Researchers reviewed five existing clinical trials to see if the anti-inflammatory drug colchicine could help prevent major heart problems in adults who already have heart disease from clogged arteries. The studies compared low-dose colchicine to a placebo or no treatment. The main goal was to see if the drug reduced a combination of four major heart events, including heart attack and stroke.
When combining the data, the initial analysis suggested colchicine was linked to a 32% lower risk of these major heart events. However, the results from the five individual trials were very different from each other, which makes the overall finding less reliable. When the researchers used a more cautious statistical method that accounts for this variation, the result was no longer statistically significant.
There was no clear sign that colchicine increased the risk of death from non-heart-related causes. However, people taking colchicine were about twice as likely to stop the drug due to stomach or intestinal side effects. The main reason for caution is that the benefit seen is not yet solid. The wide variation between studies means the true effect could be smaller, or even non-existent, in some groups of patients. Readers should understand this is an early, exploratory look at the data. More and larger studies are needed to confirm if colchicine is a safe and effective long-term treatment for preventing heart events.